Chemocentryx

ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion.

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephrology (ASN) Kidney Week 2022 and American College of Rheumatology (ACR) Convergence 2022 annual meetings taking place in November.

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

Akero Therapeutics Inc

Biogen

bluebird bio

Forma Therapeutics Holdings

iShares Nasdaq Biotechnology ETF

Karuna Therapeutics Inc

Novo Nordisk

Pfizer

Rhythm Pharmaceuticals

SPDR S&P Biotech ETF

Biotechs are relatively better positioned in this fourth quarter compared to the broader market. Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach.

Biotech Stocks Well-Positioned For Fourth Quarter

Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?

-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced two upcoming poster presentations for CCX559, the Company's investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston, MA.

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Aerie Pharmaceuticals

Belite Bio Inc

Catalyst Pharmaceuticals

Verona Pharma

Gossamer Bio Inc

Relmada Therapeutics Inc

Viridian Therapeutics

Ventyx Biosciences

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year appeared first on Investor's Business Daily.

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of ChemoCentryx, Inc. (“ChemoCentryx”) (NASDAQ: CCXI) breached their fiduciary duties to ChemoCentryx and its shareholders. If you are a ChemoCentryx shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com. Scott+Scott is

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.'s Directors and Officers for Breach of Fiduciary Duties – CCXI

VanEck Vectors Biotech ETF

Invesco Dow Jones Industrial Average Dividend ETF

Mirati Therapeutics

Cancer-drug maker Amgen solidified its position in a highly competitive market by acquiring its rival Mirati Therapeutics.

Cancer-Drug Maker's Solid Position And Successful Drug Record Drive Growth

ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?

Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?

1Life Healthcare

Shift Technologies

NEW YORK , Aug. 25, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: 1Life Healthcare, Inc. (NASDAQ: ONEM)'s  sale to Amazon.com, Inc. for $18.00 per share in cash. If you are a 1Life shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates ONEM, CCXI, AERI, SFT

SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and September, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis, as well as the role of C5a and C5aR in severe hidradenitis suppurativa (HS) and lupus nephritis (LN).

ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences

Apellis Pharma

Beam Therapeutics

Fate Therapeutics

Global Blood Therapeutics

Intellia Therapeutics

PTC Therapeutics

Repligen

Twist Bioscience Corp

Barron's screened for stocks such as Global Blood Therapeutics and Karuna Therapeutics that popped this summer.

10 Stocks Driving the Biotech Resurgence

Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

ChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy?

Merck

Seagen

SPDR S&P Pharmaceuticals ETF

Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.

Get ready for more merger mania in pharma sector the rest of the year

NEW YORK , Aug. 9, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating ChemoCentryx, Inc. (CCXI), relating to its proposed acquisition by Amgen Inc. Under the terms of the agreement, CCXI shareholders are expected to receive $52.00 in cash per share they own. Click here for more information: https://www.monteverdelaw.com/case/chemocentryx-inc.

Shareholder Alert - The M&A Class Action Firm Announces the Investigation of ChemoCentryx, Inc. - CCXI

SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx.

ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

ChemoCentryx (CCXI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

ChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last?

On Thursday, shares of ChemoCentryx Inc. ( CCXI , Financial) shot up more than 110% before closing the day at $50.43 on the news that the small-cap biotech company has entered into an agreement to be acquired by major drugmaker Amgen Inc. ( AMGN , Financial) in an all-cash deal worth $3.7 billion, or $52 per share.

ChemoCentrix Spikes 110% on Amgen Acquisition Deal

NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI), in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN).Under the terms of the merger agreement, the Company's shareholders will receive $52.00 in cash for each share of ChemoCentryx common stock owned. The transaction is valued at approximately $3.7 billion.

SHAREHOLDER ALERT: Weiss Law Investigates ChemoCentryx, Inc

Amgen narrowed its outlook for 2022 sales late Thursday after its second-quarter beat. But Amgen stock fell just a fraction.

Amgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx

Wilmington, Delaware--(Newsfile Corp. - August 4, 2022) - Rigrodsky Law, P.A. is investigating ChemoCentryx, Inc. ("ChemoCentryx") (NASDAQ: CCXI) regarding possible breaches of fiduciary duties and other violations of law related to ChemoCentryx's agreement to be acquired by Amgen. Under the terms of the agreement, ChemoCentryx's shareholders will receive $52.00 per share.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-chemocentryx-inc.To contact Seth D. Rigrodsky or Gina M.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating ChemoCentryx, Inc. Buyout

Shares of ChemoCentryx, Inc. (NASDAQ: CCXI) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. Why Is It Moving?

ChemoCentryx Shares Are Jumping 110% Thursday: Here's Why

Source: Shutterstock ChemoCentryx (NASDAQ: CCXI ) stock is rocketing higher on Thursday as investors react to news of an acquisition deal with Amgen (NASDAQ: AMGN ). This deal has Amgen agreeing to acquire ChemoCentryx for $3.7 billion in cash.

ChemoCentryx (CCXI) Stock Soars 100% on Amgen Acquisition

MILWAUKEE , Aug. 4, 2022 /PRNewswire/ -- Ademi LLP is investigating ChemoCentryx (NASDAQ: CCXI) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen.  Click here to learn how to join the action: https://www.ademilaw.com/case/chemocentryx-inc-0 or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether ChemoCentryx, Inc. has obtained a Fair Price in its transaction with Amgen

News for Chemocentryx Stock (CCXI)